A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first time in human study enrolling approximately 33 healthy adult
subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the
safety, tolerability and PK of MEDI4893 in healthy adult volunteers administered as a single
IV dose compared with placebo, across 4 cohorts. The 4 dose cohorts will enroll sequentially.
Subjects will be followed for safety from the time of Informed Consent through 360 days post
dose.